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A B S T R A C T   
Background: Arterial lactate is an established risk marker in patients with pulmonary embolism (PE). However, its 
clinical applicability is limited by the need of an arterial puncture. In contrast, venous lactate can easily be 
measured from blood samples obtained via routine peripheral venepuncture. 
Methods: We investigated the prognostic value of venous lactate with regard to in-hospital adverse outcomes and 
mortality in 419 consecutive PE patients enrolled in a single-center registry between 09/2008 and 09/2017. 
Results: An optimised venous lactate cut-off value of 3.3 mmol/l predicted both, in-hospital adverse outcome (OR 
11.0 [95% CI 4.6–26.3]) and all-cause mortality (OR 3.8 [95%CI 1.3–11.3]). The established cut-off value for 
arterial lactate (2.0 mmol/l) and the upper limit of normal for venous lactate (2.3 mmol/l) had lower prognostic 
value for adverse outcomes (OR 3.6 [95% CI 1.5–8.7] and 5.7 [95% CI 2.4–13.6], respectively) and did not 
predict mortality. If added to the 2019 European Society of Cardiology (ESC) algorithm, venous lactate <2.3 
mmol/l was associated with a high negative predictive value (0.99 [95% CI 0.97–1.00]) for adverse outcomes in 
intermediate-low-risk patients, whereas levels ≥3.3 mmol/l predicted adverse outcomes in the intermediate- 
high-risk group (OR 5.2 [95% CI 1.8–15.0]). 
Conclusion: Venous lactate above the upper limit of normal was associated with increased risk for adverse out-
comes and an optimised cut-off value of 3.3 mmol/l predicted adverse outcome and mortality. Adding venous 
lactate to the 2019 ESC algorithm may improve risk stratification. Importantly, the established cut-off value for 
arterial lactate has limited specificity in venous samples and should not be used.   
1. Introduction 
Pulmonary embolism (PE) is associated with high morbidity and 
mortality, making it a major contributor to global disease burden. [1,2] 
Thus, current guideline recommendations emphasize the importance of 
early risk stratification in the heterogeneous group of normotensive PE 
patients to guide therapeutic decision making. [2] The main determi-
nant of adverse outcomes in PE patients is right ventricular (RV) failure 
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due to the occlusion of the pulmonary vasculature by embolised 
thrombi, that may progress to manifest obstructive shock. [3] Lactate is 
a marker of the adequacy of tissue perfusion and has been shown to 
correlate with disease severity in a variety of shock states, ranging from 
sepsis to trauma and cardiogenic shock. [4-6] Previous reports indicate 
that arterial lactate levels at presentation predict outcome in acute PE 
patients and can be used to improve existing risk stratification algo-
rithms. [7-10] Although these results appear promising, their clinical 
application is restricted by the need to obtain arterial blood samples. 
While peripheral venous access is routinely established in all emergency 
patients, the need of an arterial puncture demands additional time, can 
be technically challenging and, importantly, increases the risk of 
bleeding if thrombolysis is performed due to secondary hemodynamic 
instability. 
Although much easier to obtain, lactate concentrations in peripheral 
venous samples may differ from arterial levels, especially in settings of 
inadequate tissue perfusion. [11] Prior investigations comparing arterial 
and venous lactate levels in emergency patients reported a tendency of 
venous lactate to be higher than arterial lactate. [12,13] Hence, con-
cerns arose that using the same cut-off values for venous and arterial 
lactate may lead to false positive results. [11] Therefore, it remains 
uncertain whether the prognostic value of arterial lactate also applies to 
venous lactate and if the same cut-off values can be used to risk-stratify 
patients with acute PE. Thus, we aimed to investigate the prognostic 
value of peripheral venous lactate concentrations for the prediction of 
adverse outcomes in acute PE, to establish an optimised cut-off value 
and evaluate the potential benefits of venous lactate in addition to 
existing risk stratification algorithms. 
2. Materials and methods 
2.1. Study design and definition of outcomes 
The Pulmonary Embolism Registry of Göttingen (PERGO) prospec-
tively includes consecutive patients with objectively confirmed PE ≥18 
years of age admitted to the University Medical Center Göttingen, Ger-
many. The study protocol has been described in detail previously. [14, 
15] The present analysis included patients enrolled in PERGO between 
September 2008 and March 2018. We excluded patients with (i) missing 
peripheral venous lactate measurements within six hours of presenta-
tion, (ii) high-risk PE according to the definition provided in the 2019 
ESC guidelines [2], (iii) significant concomitant acute cardio-respiratory 
illness, such as acute myocardial infarction, left heart decompensation 
or respiratory decompensation responsible for clinical presentation and 
symptoms and (iv) subsegmental PE as an incidental finding during 
diagnostic work-up for another suspected disease. All patients were 
followed for the in-hospital stay and one-year survival status was 
assessed by contacting the responsible registration offices. 
Diagnostic and therapeutic management was in accordance with the 
ESC 2008 (09/2008–08/2014) and 2014 (09/2014–03/2018) guide-
lines [16,17] and local standard operating procedures. All related de-
cisions were left to the discretion of the treating physicians and not 
influenced by the study protocol. Treating physicians were not informed 
about study results, thus any influence of the study on patient man-
agement or monitoring of treatment effects can be excluded. The study 
was conducted in accordance with the amended Declaration of Helsinki 
and was approved by the local independent Ethic Committee of the 
Medical University Göttingen, Germany (application number: 14/6/10); 
all patients gave informed written consent for participation in the study. 
Patients were stratified to risk classes according to the simplified 
Pulmonary Embolism Severity Index (sPESI) and the algorithm proposed 
by the 2019 ESC guidelines. [2] For calculation of all algorithms and 
scores, missing values were considered to be normal. [18] Tachycardia 
was defined as heart rate ≥100 beats per minute (bpm), hypotension as 
systolic blood pressure <90 mmHg and hypoxaemia as peripheral oxy-
gen saturation <90%. Renal insufficiency was defined as a glomerular 
filtration rate (GFR) <60 ml/min/1.73 m2 body surface area. Active 
cancer was defined as known malignancy, treatment with antitumour 
therapy within the last 6 months, metastatic state or hematologic cancer 
that was not in complete remission. [19] RV dysfunction on computed 
tomography pulmonary angiography (CTPA) was defined as right-to-left 
ventricular (RV/LV) diameter ratio ≥1.0. [2] 
The primary study outcome was an in-hospital adverse outcome, 
defined as PE-related death, cardiopulmonary resuscitation or vaso-
pressor treatment. Further study outcomes included in-hospital and one- 
year all-cause mortality. Death was determined to be PE-related if either 
confirmed by autopsy or following a clinically severe episode of acute PE 
in absence of an alternative diagnosis. All events and causes of death 
were independently adjudicated by two of the authors (M.E. and C.S.) 
and disagreement was resolved by a third author (M.L.). 
2.2. Biomarker measurements 
Venous blood sampling was performed via peripheral venepuncture 
on admission or at the time of PE diagnosis as a part of routine clinical 
management. Routine venous blood gas analyses were performed using 
a standard point-of-care full blood gas analyses assay (GEM Premier 
4000 analyser; Instrumentation Laboratory, Kirchheim, Germany). 
Plasma concentrations of high-sensitivity troponin T (hsTnT; Roche 
Diagnostics, Mannheim, Germany) were measured by the amedes MVZ 
wagnerstibbe laboratory in Göttingen, Germany and elevated concen-
trations were prospectively defined as ≥14 pg/ml. [18] 
2.3. Statistical analysis 
Categorical variables are presented as total numbers and percent-
ages; continuous variables are presented as medians with interquartile 
ranges (IQR). Associations between binary and categorical variables 
were analysed using Fisher’s exact test, Chi-square test or the Mantel- 
Haenszel test of trend, as appropriate. Spearman’s rank correlation co-
efficient was used to test for statistical dependence of venous lactate 
from continuous variables. For comparison of continuous variables, the 
Mann-Whitney U test was employed. 
To investigate the prognostic performance of venous lactate levels 
with regard to study outcomes, receiver operating characteristic (ROC) 
curve analyses were performed to determine the area under the curve 
(AUC) with corresponding 95% confidence intervals (CIs). Youden index 
quantification was used to identify the optimal cut-off value for pre-
diction of the primary study outcome. 
The prognostic performance of the established cut-off value for 
arterial lactate (2.0 mmol/l), the upper limit of normal for venous 
lactate (2.3 mmol/l) and the newly identified optimised cut-off value 
was expressed in terms of sensitivity, specificity, positive and negative 
predictive value and positive likelihood ratios. The prognostic value of 
the three lactate cut-off values and further parameters with regard to 
study outcomes was tested using univariable logistic regression analyses 
and results are presented as odds ratios (OR) with the corresponding 
95% CI. To confirm the independent prognostic value of venous lactate, 
all predictors of study outcomes identified in univariate logistic 
regression analyses were entered in a multivariable logistic regression 
model with forward stepwise selection (inclusion criterion: p-value of 
the score test ≤5%; exclusion criterion: p-value of the likelihood-ratio 
test ≥10%). 
To investigate the incremental value of venous lactate in addition to 
the 2019 ESC risk assessment algorithm for prediction of adverse in- 
hospital outcomes, we performed a hierarchical binary logistic regres-
sion analysis. In step 1 the model included 2019 ESC risk classes only 
and in step 2 categorial information on venous lactate levels (group 1 =
<2.3 mmol/l; group 2 = 2.3–3.2 mmol/l; group 3 = ≥3.3 mmol/l) were 
added. Likelihood-ratio chi2, Nagelkerke pseudo-R2, Hosmer-Lemeshow 
test and Harrell’s c-statistic were calculated. To evaluate the potential 
benefit of a modified version of the 2019 ESC risk assessment algorithm 
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that further stratified intermediate-risk patients based on venous lactate, 
we calculated user category net reclassification improvement (NRI) with 
the corresponding standard error. [20] Kaplan-Meier analysis was used 
to compare the probability of one-year survival in subgroups stratified 
according to lactate levels at presentation; the log-rank test was used for 
comparison between groups. 
A two-sided significance level of α<0.05 was defined appropriate to 
indicate statistical significance. As this was an explorative testing, no 
adjustments for multiple testing were carried out. P-values were pro-
vided for descriptive reasons only and should be interpreted with 
caution and in connection with effect estimates. Statistical analysis was 
performed through Statistics Package for Social Sciences (IBM SPSS 
Statistics, Version 26, IBM Corp. Armonk, NY). 
3. Results 
Between September 2008 and March 2018, 851 patients were 
enrolled in PERGO. Exclusion criteria applied to (i) 279 (32.8%) patients 
with missing venous lactate measurements at presentation, (ii) 86 
(10.1%) patients with high-risk PE, (iii) 25 (2.9%) patients with sig-
nificant concomitant acute cardio-respiratory illness and (iv) 42 (4.9%) 
patients with subsegmental PE as an incidental finding. Hence, 419 
(49.2%) patients were included in the present analysis. 
At presentation, 45 (10.7%) patients were classified as low-risk, 211 
(50.4%) as intermediate-low-risk and 161 (38.4%) as intermediate-high- 
risk according to the 2019 ESC risk stratification algorithm. An in- 
hospital adverse outcome occurred in 24 (5.7%) patients. Overall, 17 
(4.1%) patients died during the in-hospital stay; of those, 10 (58.8%) 
due to PE. Further information on comorbidities, initial presentation and 
outcomes is shown in Table 1, left column. A comparison of study pa-
tients and patients excluded due to missing lactate measurements is 
provided in Table s1 of the Online Supplement. 
The median venous lactate concentration on admission was 1.6 (IQR 
1.2–2.4) mmol/l. Venous lactate concentrations showed a positive cor-
relation with heart rate (r = 0.32, p<0.001) and an inverse correlation 
with systolic blood pressure (r=− 0.13, p = 0.008). 
Patients who suffered an in-hospital adverse outcome had higher 
venous lactate concentrations than patients with a favourable clinical 
course (3.1 [IQR 1.3–4.9] mmol/l vs. 1.6 [IQR 1.2–2.3] mmol/l, p =
0.001). The rate of in-hospital adverse outcomes was associated with 
increasing lactate concentrations at presentation (p <0.001 for trend; 
Fig. 1). 
Using ROC analysis, we calculated an AUC of 0.70 (95% CI 
0.57–0.84) for the prediction of an in-hospital adverse outcome and 
identified a venous lactate concentration of 3.3 mmol/l as the optimal 
cut-off value. Of note, Youden’s indices for the cut-off values 2.3 mmol/l 
and 3.3 mmol/l were almost identical (0.41 vs. 0.42). A comparison of 
test characteristics for the optimal cut-off value and prespecified cut-off 
values is presented in Table 2. Due to the superior specificity provided 
by the 2.3 mmol/l and 3.3 mmol/l cut-off values compared to 2.0 mmol/ 
l, all further analyses in the main manuscript are based on these two 
values. Moreover, results of risk stratification based on the 2.0 mmol/l 
cut-off value are provided in the Online Supplement. 
Baseline characteristics and results of risk stratification in patients 
stratified to venous lactate cut-off values of 2.3 mmol/l and 3.3 mmol/l 
are provided in Table 1, middle and right columns. Patients with 
elevated venous lactate more frequently presented with syncope and 
had higher rates of tachycardia, hypoxaemia, elevated troponin levels 
and signs of RV dysfunction on CTPA. 
Venous lactate ≥2.3 mmol/l was observed in 119 (28.4%) patients 
and predicted an in-hospital adverse outcome (OR 5.7 [95% CI 
2.4–13.6]; Table 2) but not all-cause mortality (OR 1.8 [95% CI 
Table 1 
Comorbidities, results from risk stratification and outcomes of study patients stratified to venous lactate levels.   
All patients (n ¼ 419) Venous lactate ≥2.3 mmol/l (n ¼ 119) p-valuea Venous lactate ≥3.3 mmol/l (n ¼ 45) p-valueb 
Age ≥75 years 160 (38.2%) 53 (44.5%) 0.09 20 (44.4%) 0.36 
Sex (female) 220 (52.5%) 64 (53.8%) 0.74 21 (46.7%) 0.41 
Comorbidities 
Chronic heart failure 60 (14.3%) 20 (16.8%) 0.36 9 (20%) 0.25 
Coronary artery disease 64 (15.3%) 14 (11.8%) 0.21 7 (15.6%) 0.96 
Chronic pulmonary disease 57 (13.6%) 15 (12.6%) 0.71 6 (13.3%) 0.96 
Diabetes mellitus 68 (16.2%) 30 (25.2%) 0.002 15 (33.3%) <0.001 
Renal insufficiency 142 (34.1%), n = 417 50 (42%) 0.03 25 (55.6%) 0.001 
Active cancer 64 (15.3%), n = 418 24 (20.3%), n = 118 0.07 8 (17.8%) 0.63 
Symptoms at presentation 
Dyspnea 346 (83.2%), n = 416 93 (78.2%) 0.08 32 (71.1%) 0.022 
Syncope 60 (14.4%), n = 417 30 (25.2%) <0.001 16 (35.6%) <0.001 
Clinical findings at presentation 
Tachycardia 167 (40.1%), n = 416 70 (58.8%) <0.001 31 (68.9%) <0.001 
Hypoxaemia 92 (23.2%), n = 396 43 (37.1%), n = 116 <0.001 18 (41.9%), n = 43 0.002 
Laboratory and imaging markers 
hsTnT ≥14 pg/ml 266 (66.7%), n = 399 93 (83.8%), n = 111 <0.001 37 (86.0%), n = 43 0.004 
RV/LV diameter ratio ≥1.0 on CTPA 245 (76.6%), n = 320 80 (86.0%), n = 93 0.011 30 (81.1%), n = 37 0.49 







































In-hospital all-cause mortality 17 (4.1%) 8 (5.6%) 0.23 5 (11.1%) 0.011 
Reperfusion treatment 19 (4.5%) 24 (16.9%) <0.001 8 (17.8%) <0.001 
Statistically significant results are marked in bold letters. 
Abbreviations: HsTnT denotes high sensitivity troponin T; RV/LV, right/left ventricle; CTPA, computed tomography pulmonary angiography; ESC, European Society of 
Cardiology; PE, pulmonary embolism.Prognostic value of venous lactate. 
a compared to patients with venous lactate <2.3 mmol/l. 
b compared to patients with venous lactate <3.3 mmol/l. 
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0.7–4.9]). Venous lactate ≥3.3 mmol/l was observed in 45 (10.7%) 
patients and predicted both, an in-hospital adverse outcome (OR 11.0 
[95% CI 4.6–26.3]) and all-cause mortality (OR 3.8 [95% CI 1.3–11.3]; 
Table 2). When entered in multivariable models that included all 
outcome predictors identified based on the results of univariate logistic 
regression analyses, the independent prognostic value of the two 
investigated cut-off values with regard to the study outcomes was 
confirmed (Table 3). 
Data on one-year mortality of patients stratified according to venous 
lactate levels at presentation are provided in the Online Supplement. 
3.1. Venous lactate for risk stratification 
If venous lactate was added to the 2019 ESC algorithm, the fit of a 
hierarchical binary logistic regression model (including 2019 ESC risk 
classes [step 1] and categories of venous lactate elevation [step 2]) 
Fig. 1. Rate of an in-hospital adverse outcome stratified to venous lactate level at presentation.  
Table 2 
Prognostic performance of different venous lactate cut-off values with regard to (A) in-hospital adverse outcome and (B) all-cause mortality.  
A: In-hospital adverse outcome  
Prevalence In-hospital adverse 
outcome rate 




PPV (95% CI) NPV (95% CI) LRþ OR  (95% CI) 
Venous lactate  ≥2.0 
mmol/l 








1.9 3.64 (1.52–8.73) 
Venous lactate  ≥2.3 
mmol/l 










Venous lactate  ≥3.3 
mmol/l 










B: In-hospital all-cause mortality  
Prevalence In-hospital mortality 
rate 




PPV (95% CI) NPV (95% CI) LRþ OR  (95% CI) 
Venous lactate  ≥2.0 
mmol/l 








1.1 1.19  (0.44–3.19) 
Venous lactate  ≥2.3 
mmol/l 








1.5 1.81  (0.67–4.48) 
Venous lactate  ≥3.3 
mmol/l 










Statistically significant results are marked in bold letters. 
Abbreviations: CI denotes confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; OR, odds ratio. 
Table 3 
Predictors of (A) in-hospital adverse outcome and (B) all-cause mortality identified using univariable and multivariable logistic regression models.  
A: In-hospital adverse outcome  
Univariable model Multivariable model 1 Multivariable model 2  
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Renal insufficiency 2.90 (1.25–6.7) 0.01 – 0.13 – 0.36 
Syncope 3.51 (1.42–8.68) 0.004 – 0.15 – 0.30 
Venous lactate ≥2.3 mmol/l 5.67 (2.36–13.64) <0.001 5.10 (2.01–12.98) 0.001 Not included 
Venous lactate ≥3.3 mmol/l 10.97 (4.57–26.34) <0.001 Not included 9.68 (3.89–24.10) <0.001 
hsTnT ≥14 pg/ml 12.49 (1.67–93.55) 0.002 8.03 (1.05–61.54) 0.045 8.67 (1.13–66.49) 0.038 
B: In-hospital all-cause mortality  
Univariable model Multivariable model 3  
OR (95% CI) p-value OR (95% CI) p-value 
Active cancer 3.23 (1.15–9.06) 0.019 3.02 (1.05–9.85) 0.041 
Venous lactate ≥3.3 mmol/l 3.77 (1.26–11.25) 0.011 3.20 (1.04–9.85) 0.042 
hsTnT ≥14 pg/ml 8.45 (1.11–64.4) 0.014 6.98 (0.90–53.83) 0.06 
Statistically significant results are marked in bold letters. 
Abbreviations: OR denotes odds ratio; CI, confidence interval; hsTnT, high sensitivity troponin T. 
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improved (chi2 = 18.17; p <0.001), and results of the Hosmer- 
Lemeshow test remained non-significant for both models (p = 0.498 
and p = 0.322, respectively). The overall fit of the model assessed using 
Nagelkerke pseudo-R2 increased from 0.086 to 0.202 and the c-index 
improved from 0.69 (95% CI 0.59–0.79) to 0.82 (95% CI 0.74–0.89). 
Further, as shown in Fig. 2 and Figure s3 of the Online Supplement, 
venous lactate concentrations ≥2.3 mmol/l identified patients with 
higher rates of an adverse outcome in intermediate-low risk patients (p 
<0.001) and provided an OR for adverse outcome prediction of 22.5 
(95% CI 2.6–191.6). Conversely, venous lactate <2.3 mmol/l had a 
negative predictive value for the occurrence of an adverse outcome of 
0.99 (95% CI 0.97–1.00), resulting in a net reclassification improvement 
(NRI; 0.65±0.16, p <0.001). In the intermediate-high risk group, venous 
lactate ≥3.3 mmol predicted adverse outcomes with an OR of 5.2 (95% 
CI 1.8–15.0), but NRI slightly failed to reach statistical significance 
(0.32±0.17, p = 0.06). 
4. Discussion 
In the present study, we evaluated the prognostic value of venous 
lactate in normotensive PE patients. Our findings obtained in 419 pa-
tients can be summarised as follows: (i) venous lactate above the upper 
limit of normal (2.3 mmol/l) was associated with an increased risk for an 
in-hospital adverse outcome, (ii) lactate concentrations exceeding an 
optimised cut-off value of 3.3 mmol/l were predictive of both an in- 
hospital adverse outcome and all-cause mortality, (iii) the previously 
proposed cut-off value for arterial lactate of 2.0 mmol/l has low prog-
nostic value in venous samples and should not be used and (iv) infor-
mation on venous lactate added to the 2019 ESC algorithm may further 
improve risk stratification of normotensive PE patients. 
Haemodynamic instability due to RV failure is the main reason for 
adverse outcomes in PE patients. Accordingly, risk stratification of acute 
PE in based on signs indicating myocardial dysfunction or damage, e.g. 
RV dilation on diagnostic imaging and elevated troponin levels. [2] 
However, these markers provide only indirect information on the ade-
quacy of cardiac output, the critical determinant of haemodynamic 
impairment. Direct assessment of peripheral (hypo)perfusion using 
plasma lactate measurements might therefore be a more specific indi-
cator of threatening haemodynamic instability. 
This concept is supported by previous investigations that investi-
gated the role of arterial lactate for outcome prediction in both, unse-
lected and normotensive patients with PE. [7-10,21] In a cohort of 287 
unselected PE patients, Vanni et al. identified an arterial lactate cut-off 
value of 2.0 mmol/l to predict in-hospital mortality with an OR of 4.6 
(95% CI 1.4–17.6). [7] This cut-off value was later validated in 270 
unselected PE patients included the prospective Thrombo Embolism 
Lactate Outcome Study (TELOS). [8] In a cohort of normotensive PE 
patients, arterial lactate ≥2.0 mmol/l increased the risk of developing 
PE-related complications (OR 6.9 [95% CI 2.6–18.2]) and 30-day 
all-cause mortality (OR 2.5; 95% CI 1.1–5.5). [9] Finally, information 
on arterial lactate has been integrated in different risk assessment stra-
tegies such as the expanded BOVA score and the SHIelD score for 
improved risk prediction in intermediate-risk PE patients. [10,21] 
Unfortunately, the clinical applicability of these uniformly positive 
results is limited by the requirement of obtaining an arterial blood 
sample. An arterial puncture demands additional time, requires special 
training of the personnel and subjects patients to pain and inconve-
nience. [11] Furthermore, arterial punctures present an additional 
bleeding risk in patients treated with thrombolytic therapy due to hae-
modynamic worsening. 
To overcome this important limitation, the present study investi-
gated whether a similar prognostic value is provided by lactate 
measured from peripheral venous samples, that can be easily obtained 
during a routine (venous) blood draw. Our results confirm the study 
hypothesis. Even modest venous lactate elevations above the upper limit 
of normal (2.3 mmol/l) increased the odds of an in-hospital adverse 
outcome. Optimal prognostic performance was observed for a venous 
lactate cut-off value of 3.3 mmol/l, that predicted adverse outcomes as 
well as all-cause mortality. 
Even though peripheral venous and arterial lactate concentrations 
are highly correlated, venous levels are on average about 0.2 to 0.3 
mmol/l higher compared to arterial concentrations. [11,13] This might 
explain why the previously identified arterial cut-off value (2.0 mmol/l) 
[7], that lies within the normal range for venous samples, had lower 
specificity compared to the other investigated cut-off values (Table 2). 
Thus, it should not be used when interpreting venous lactate for risk 
stratification purposes. 
Venous lactate adds to the predictive value of the 2019 ESC risk 
assessment algorithm. In intermediate-low-risk patients, non-elevated 
venous lactate (<2.3 mmol/l) excluded the occurrence of an adverse 
outcome with a negative predictive value of more than 99%, while in 
intermediate-high-risk patients venous lactate ≥3.3 mmol/l identified a 
subgroup at increased risk for developing adverse outcomes (Fig. 2). 
4.1. Limitations 
Of note, a considerable number of patients were excluded from the 
study due to missing lactate measurements at presentation. However, 
Fig. 2. Venous lactate for risk stratification in addition to the 2019 ESC algorithm Abbreviations: PE denotes pulmonary embolism; ESC, European Society 
of Cardiology. 
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the comparison of patients with and without lactate measurements 
provided in Table s1 did not reveal relevant differences between the two 
groups. The small number of patients with an adverse outcome (5.7%) 
and with a venous lactate concentration ≥3.3 mmol/l (10.7%) may have 
impaired the ability to detect statistically significant differences be-
tween subgroups. Furthermore, the single-center design limits the 
generalizability of our findings. 
4.2. Conclusion 
Our results confirm the prognostic value of peripheral venous lactate 
in normotensive patients with acute PE. An increased risk for an in- 
hospital adverse outcome was observed in all patients with venous 
lactate concentrations exceeding the upper limit of normal (≥2.3 mmol/ 
l) and a cut-off value of 3.3 mmol/l provided optimal prognostic per-
formance predicting both, an in-hospital adverse outcome and all-cause 
mortality. If added to the 2019 ESC algorithm, information on venous 
lactate may further improve risk stratification of intermediate-risk 
patients. 
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